Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own1.20% Shs Outstand45.79M Perf Week5.22%
Market Cap1.25B Forward P/E38.64 EPS next Y0.70 Insider Trans135.49% Shs Float45.75M Perf Month15.25%
Income-42.90M PEG- EPS next Q0.65 Inst Own- Short Float13.76% Perf Quarter21.43%
Sales535.10M P/S2.33 EPS this Y-401.70% Inst Trans2.11% Short Ratio7.84 Perf Half Y70.00%
Book/sh15.01 P/B1.81 EPS next Y-59.75% ROA-3.20% Target Price22.88 Perf Year34.65%
Cash/sh- P/C- EPS next 5Y29.00% ROE-6.40% 52W Range13.60 - 33.00 Perf YTD44.68%
Dividend- P/FCF55.60 EPS past 5Y-24.60% ROI-3.00% 52W High-17.58% Beta1.68
Dividend %- Quick Ratio2.00 Sales past 5Y12.20% Gross Margin78.80% 52W Low100.00% ATR0.93
Employees597 Current Ratio2.40 Sales Q/Q9.30% Oper. Margin-3.30% RSI (14)63.97 Volatility3.40% 4.24%
OptionableYes Debt/Eq0.00 EPS Q/Q55.80% Profit Margin-8.00% Rel Volume0.77 Prev Close26.70
ShortableYes LT Debt/Eq0.48 EarningsOct 31 BMO Payout- Avg Volume803.00K Price27.20
Recom2.70 SMA207.62% SMA5015.54% SMA20028.47% Volume619,293 Change1.87%
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Apr-22-15Resumed Piper Jaffray Neutral
Feb-12-15Initiated MLV & Co Buy $58
Oct-30-14Reiterated MKM Partners Neutral $31.50 → $33
Aug-19-14Resumed Stifel Buy $47
May-07-14Reiterated MKM Partners Neutral $33 → $31.50
Apr-17-14Initiated Canaccord Genuity Hold $37
Apr-14-14Upgrade FBR Capital Mkt Perform → Outperform $30 → $47
Nov-01-13Upgrade MKM Partners Sell → Neutral
Nov-01-13Reiterated FBR Capital Outperform $35 → $30
Oct-30-13Initiated FBR Capital Mkt Perform $35
Oct-01-13Reiterated Aegis Capital Buy $43 → $50
Oct-19-17 09:00AM  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi Zacks
Oct-18-17 04:59PM  Pricing Pressure, Competition Remain Headwinds for Pharma Stocks Zacks
Oct-10-17 07:00AM  Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled for October 31, 2017 Business Wire
Oct-09-17 04:39PM  Acorda Therapeutics Inc (ACOR): How Does It Impact Your Portfolio? Simply Wall St.
Oct-04-17 08:05AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
Oct-03-17 08:06AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
03:00AM  Acorda Therapeutics Shows Market Leadership With Jump To 91 RS Rating Investor's Business Daily
Oct-02-17 08:05AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit +9.94%
Sep-26-17 03:00AM  Acorda Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Sep-25-17 03:55PM  ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm PR Newswire
Sep-21-17 08:06AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
Sep-18-17 08:06AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
Sep-13-17 07:00AM  Acorda to Present at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-12-17 08:01PM  Should You Buy Acorda Therapeutics Inc (ACOR) Now? Simply Wall St.
08:04AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
Sep-11-17 03:00AM  Acorda Therapeutics Earns RS Rating Upgrade Investor's Business Daily
Sep-08-17 01:22PM  INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. Business Wire
Sep-07-17 11:59AM  ETFs with exposure to Acorda Therapeutics, Inc. : September 7, 2017 Capital Cube
03:00AM  Stocks Showing Rising Market Leadership: Acorda Therapeutics Earns 83 RS Rating Investor's Business Daily
Sep-05-17 05:39PM  ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm Business Wire
02:19PM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Capital Cube
07:40AM  Featured Company News Acorda Therapeutics Adopts Poison Pill ACCESSWIRE
Sep-01-17 10:24PM  Acorda Therapeutics, Inc. Value Analysis (NASDAQ:ACOR) : September 2, 2017 Capital Cube
07:00AM  Acorda Adopts Shareholder Rights Plan Business Wire
Aug-31-17 08:42AM  Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update Zacks +6.39%
Aug-30-17 07:14PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Acorda Therapeutics, Inc. Business Wire
03:55PM  ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm ACCESSWIRE
11:44AM  AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug Zacks
11:06AM  FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down Zacks
10:10AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics Inc. (ACOR) PR Newswire
09:18AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ACOR-US : August 30, 2017 Capital Cube
08:20AM  Today's Research Reports on Stocks to Watch: ImmunoGen, Inc. and Acorda Therapeutics Inc. ACCESSWIRE
08:19AM  Acorda Therapeutics (ACOR) Alert: Shareholder Rights Law Firm J&W Investigates Acorda Therapeutics, Inc.; Encourages Investors to Contact the Firm PR Newswire
Aug-29-17 06:33PM  Acorda Therapeutics, Inc. Investor Alert: Legal Investigation for Potential Securities Law Violations Business Wire -24.32%
05:07PM  What Happened in the Stock Market Today Motley Fool
04:06PM  Acorda Dives To 10-Week Low After FDA Refuses Parkinson's Drug Investor's Business Daily
03:30PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Acorda Therapeutics, Inc. Business Wire
02:52PM  Acorda stock plummets 26% on surprising, puzzling, disconcerting FDA drug decision MarketWatch
02:18PM  Why Acorda Therapeutics Is Losing One-Quarter of Its Value Today Motley Fool
01:29PM  ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm Business Wire
12:50PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Acorda Therapeutics Inc. - ACOR PR Newswire
12:34PM  Adamas Pharma stock surges 7% after negative FDA decision for rival Acorda's Parkinson's treatment MarketWatch
11:39AM  INVESTOR ALERT: Investigation of Acorda Therapeutics Announced by Holzer & Holzer Business Wire
10:10AM  Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers TheStreet.com
09:50AM  Acorda Therapeutics Shares Crushed After Receipt of FDA Refusal Letter 24/7 Wall St.
09:31AM  Stocks to Watch: Finish Line, Nike, Best Buy, Hain Celestial, Acorda Therapeutics The Wall Street Journal
07:33AM  UPDATE: Acorda Therapeutics shares crater 26% premarket after FDA rejects application for Parkinson's treatment MarketWatch
07:00AM  Acorda Receives Refusal to File Letter from FDA for INBRIJA (CVT-301, levodopa inhalation powder) New Drug Application Business Wire
Aug-28-17 03:00AM  Acorda Therapeutics Earns Relative Strength Rating Upgrade Investor's Business Daily
Aug-25-17 08:06AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit +9.35%
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Acorda Therapeutics Inc. Markit
Aug-11-17 11:56PM  Edited Transcript of ACOR earnings conference call or presentation 27-Jul-17 12:30pm GMT Thomson Reuters StreetEvents
11:47PM  [$$] The Payoff in ADP Barrons.com
Aug-10-17 08:06AM  IHS Markit Score Update: Drop in demand for ETFs holding Acorda Therapeutics Inc is a negative sign for its shares Markit
Aug-07-17 08:24PM  Acorda Stiff-Arms Investor's Demand for Sale TheStreet.com
02:41PM  Activists Gonna Activate: Hedge Funds Send Letters To Acorda, Taubman Centers Boards Benzinga
10:56AM  Scopia Capital Management Takes a Stake in Acorda Therapeutics Barrons.com
08:52AM  Scopia boosts stake in Acorda Therapeutics to become the largest shareholder MarketWatch
08:35AM  Acorda Therapeutics investor calls for company to explore sale Reuters
Jul-28-17 02:33PM  Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line Zacks
08:00AM  Today's Research Reports on Trending Tickers: Astrazeneca PLC and Acorda Therapeutics Inc. ACCESSWIRE
01:24AM  Acorda reports 2Q loss Associated Press
Jul-27-17 06:00AM  Acorda Provides Financial and Pipeline Update for Second Quarter 2017 Business Wire
Jul-13-17 03:22PM  ETFs with exposure to Acorda Therapeutics, Inc. : July 13, 2017 Capital Cube
07:00AM  Acorda Second Quarter 2017 Update Webcast/Conference Call Scheduled for July 27, 2017 Business Wire
Jun-30-17 10:02AM  Acorda Files NDA for Parkinson's Disease Candidate Inbrija Zacks
Jun-29-17 04:01PM  Acorda Submits New Drug Application to U.S. Food and Drug Administration for INBRIJATM (CVT-301, Levodopa Inhalation Powder) Business Wire
Jun-26-17 03:14PM  ETFs with exposure to Acorda Therapeutics, Inc. : June 26, 2017 Capital Cube
Jun-21-17 02:18PM  Biotech Insider Just Loaded Up $234 Million Worth the Stock TheStreet.com
Jun-16-17 09:52AM  Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe TheStreet.com
Jun-15-17 12:54PM  ETFs with exposure to Acorda Therapeutics, Inc. : June 15, 2017 Capital Cube
Jun-14-17 09:20AM  Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-12-17 02:43PM  Acorda Therapeutics, Inc. Value Analysis (NASDAQ:ACOR) : June 12, 2017 Capital Cube
Jun-09-17 08:36AM  Acorda Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ACOR-US : June 9, 2017 Capital Cube
06:15AM  Zacks Initiates on Pulmatrix (NASDAQ:PULM) Zacks Small Cap Research
Jun-07-17 05:42PM  Acorda Presents Phase III Data on PD Candidate CVT-301 Zacks
08:00AM  Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics Accesswire
Jun-06-17 04:31PM  Acorda Therapeutics Inc (ACOR): Key Takeaways from CVT-301 Presentation at MDS SmarterAnalyst
10:04AM  Acorda stock surges 10% on positive late-stage Parkinson's results MarketWatch
09:31AM  Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms TheStreet.com
07:48AM  Early movers: GM, HDS, LE, MIK, GIII, THO, ACOR, RBS, BBRY & more CNBC
06:00AM  Acorda Presenting New Tozadenant Data at 2017 MDS Congress Business Wire
Jun-05-17 04:01PM  CVT-301 Phase 3 Data Showed Significantly Improved Motor Function During OFF Periods in Parkinsons Disease Business Wire
Jun-01-17 08:55AM  Why Is Acorda (ACOR) Down 8.4% Since the Last Earnings Report? Zacks +6.52%
May-31-17 07:00AM  Acorda to Present at the Goldman Sachs Healthcare Conference Business Wire
May-25-17 09:16AM  Biogen's Fampyra Conditional Approval Converted to Standard Zacks
May-18-17 07:00AM  Acorda to Present New INBRIJA (Levodopa Inhalation Powder) Phase 3 Data at Upcoming MDS Congress Business Wire
May-02-17 06:00AM  Acorda to Present at the Deutsche Bank 42nd Annual Healthcare Conference Business Wire
Apr-28-17 09:55PM  Edited Transcript of ACOR earnings conference call or presentation 27-Apr-17 12:30pm GMT Thomson Reuters StreetEvents
10:29AM  Acorda (ACOR) Q1 Loss Wider Than Expected, Revenues Miss Zacks
07:00AM  Acorda Expands Alexa Skill Offering for Parkinsons Awareness Month Business Wire
Apr-27-17 09:38PM  Acorda Shares Fall 5% in an Earnings Miss TheStreet.com -5.76%
05:31PM  Biotech And Pharma Industry And Stock News Investor's Business Daily
05:06PM  Acorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses Investor's Business Daily
04:07PM  Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports TheStreet.com
03:11PM  Acorda Topples To 11-Year Low On Street-Lagging Q1 Sales, Losses Investor's Business Daily
07:42AM  Acorda Puts 4 Drugs On Back Burner After Patent Setback Investor's Business Daily
07:15AM  CORRECTING and REPLACING Acorda Provides Financial and Pipeline Update for First Quarter 2017 Business Wire
06:28AM  Acorda reports 1Q loss Associated Press
Apr-13-17 07:00AM  Acorda to Host Conference Call to Discuss First Quarter 2017 on April 27, 2017 Business Wire
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinson's disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinson's disease; SYN120, which is in Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAWRENCE DAVIDChief, Bus. Ops & PAOOct 09Sale25.402506,3508,686Oct 11 03:57 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerAug 29Buy19.23766,20114,730,4498,474,728Aug 31 04:50 PM
Greene Barry EDirectorAug 01Option Exercise18.2110,000182,10010,000Aug 03 04:06 PM
RAUSCHER STEVEN MDirectorAug 01Option Exercise18.2110,000182,10010,000Aug 03 04:08 PM
Greene Barry EDirectorAug 01Sale21.5710,000215,6970Aug 03 04:06 PM
RAUSCHER STEVEN MDirectorAug 01Sale21.5710,000215,7030Aug 03 04:08 PM
Randall LorinDirectorJul 31Option Exercise18.2110,000182,10010,000Aug 02 04:05 PM
Randall LorinDirectorJul 31Sale21.6610,000216,6150Aug 02 04:05 PM
COHEN RONPresident and CEOJun 16Buy16.9520,000338,998511,648Jun 20 03:52 PM
Hindman Andrew A.Chief Business Dev. OfficerMay 15Sale15.757,704121,31946,123May 17 03:57 PM
Blight AndrewChief Scientific OfficerFeb 09Option Exercise22.1367,5861,495,678144,144Feb 13 04:13 PM
Greene Barry EDirectorFeb 09Option Exercise22.1372316,000723Feb 13 04:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Option Exercise22.1363,1831,398,24067,719Feb 13 04:15 PM
Wasman JanePresident, Intl and GCFeb 09Option Exercise22.1354,5361,206,882156,210Feb 13 04:16 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 09Sale22.3263,1831,410,5424,536Feb 13 04:15 PM
Greene Barry EDirectorFeb 09Sale22.6572316,3760Feb 13 04:14 PM
Blight AndrewChief Scientific OfficerFeb 09Sale22.4167,5861,514,37976,558Feb 13 04:13 PM
Wasman JanePresident, Intl and GCFeb 09Sale22.3054,5361,216,218101,674Feb 13 04:16 PM
Greene Barry EDirectorJan 03Option Exercise15.913,01748,0003,017Jan 05 04:12 PM
Greene Barry EDirectorJan 03Sale19.263,01758,1130Jan 05 04:12 PM
COHEN RONPresident and CEODec 14Option Exercise15.4940,172622,264519,860Dec 16 08:08 AM
COHEN RONPresident and CEODec 14Sale20.7540,172833,655479,688Dec 16 08:08 AM
Blight AndrewChief Scientific OfficerDec 01Sale20.764,855100,77476,558Dec 05 05:03 PM
Wasman JanePresident, Intl and GCDec 01Sale20.743,34769,400101,674Dec 05 05:15 PM
Sabella Lauren MChief Commercial OfficerDec 01Sale20.742,42950,38111,949Dec 05 05:14 PM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 01Sale20.744,41691,5944,536Dec 05 05:11 PM
Hindman Andrew A.Chief Business Dev. OfficerDec 01Sale20.724439,18049,227Dec 05 05:09 PM
COHEN RONPresident and CEODec 01Sale20.747,160148,482479,688Dec 05 05:08 PM
BLANK BURKHARDChief Medical OfficerDec 01Sale20.7410,000207,44240,000Dec 05 05:06 PM